ClinicalTrials.gg
RecruitingNCT07684508Updated Aug 5, 2026

Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer

An interventional study of Postoperative Radiotherapy in Hypofractionated Radiotherapy, Intensity-modulated Radiotherapy and Cervical Cancers, sponsored by Manni Huang. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Manni Huang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 458 studies in Uterine Cervical Neoplasms with a site in China — 208 open to participants now, 243 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
125th of 363
154 · median 89
Started
2026
with 26 others
No phase
72 of 458
36 open now
Primary completion
2030-12
later than 237 of 242 live
Registered
445th of 458
by date

Among the 458 studies in Uterine Cervical Neoplasms with a site in China, this one is the 125th largest by planned enrollment of the 363 interventional ones that give a count, is one of 27 that started in 2026, is one of 72 with no phase, reaches primary completion later than 237 of the 242 other live ones, and was the 445th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

208 of the 458 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

202 more — sign in →

All 208 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 458 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer

Read the detailed description

This multicenter, phase II trial was conducted to assess the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in patients with cervical cancer after hysterectomy. The primary endpoint was the incidence of acute grade 3 or higher gastrointestinal (GI), genitourinary (GU), and hematologic toxicities during radiotherapy (RT) or within three months after RT completion, based on the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. The secondary endpoints included late toxicities, scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) / Cervical Cancer Module (CX24), disease-free survival (DFS), and overall survival (OS).

03

Conditions studied

  • Hypofractionated Radiotherapy
  • Intensity-modulated Radiotherapy
  • Cervical Cancers
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status 0 or 1;
  • confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
  • Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;
  • For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model";
  • Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, (NEUT) ≥1.5×10⁹/L, count (PLT) ≥80×10⁹/L, (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5× (ULN) or ≥50 ml/min; hepatic function: total (TBIL) ≤1.5×ULN, (AST) or alanine aminotransferase (ALT) ≤2.5×ULN;
  • Voluntarily signed the form prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of active malignant tumor within 3 years prior to initial treatment(except for the cervical cancer)and any locally curable tumors treated with radical therapy;
  • Any high-risk factor confirmed by postoperative pathology: positive lymph node , positive parametrial invasion, or positive resection margin;
  • History of therapy prior to enrollment;
  • Local recurrence or distant metastasis prior to enrollment;
  • Postoperative intestinal obstruction or intestinal adhesion;
  • Severe cardiac, cerebral, hepatic, or renal disorders;
  • Long-term state;
  • Pregnant or lactating females;
  • Premature discontinuation of treatment for any reason;
  • Poor compliance, unwillingness to participate, or inability to cooperate with follow-up;
  • Any other conditions deemed unsuitable for this trial by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Postoperative Radiotherapy

    Patients undergo moderately hypofractionated IMRT after radical hysterectomy

    Radiation: Postoperative Radiotherapy

Interventions

  • RadiationPostoperative Radiotherapy

    Postoperative moderately hypofractionated IMRT (2.5Gy per fraction, 17 fractions, once a day)

06

What researchers measure

Primary outcomes

  1. Acute toxicities

    the incidence of acute grade 3 or higher gastrointestinal (GI), genitourinary (GU), and hematologic toxicities during radiotherapy (RT) or within three months after RT completion, based on the CTCAE version 6.0

    Time frame: 3 months

Secondary outcomes

  1. Late toxicities

    evaluation of late toxicities during three months to one year after RT completion according to CTCAE version 6.0

    Time frame: 1 year

  2. Disease-Free Survival (DFS)

    the time from initiation of study treatment to the first occurrence of locoregional recurrence, distant metastasis, or death from any cause.

    Time frame: 2-years

  3. Overall Survival (OS)

    the time from the start of study treatment to death from any cause.

    Time frame: 2-years

  4. Patient-reported quality of life

    scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) / Cervical Cancer Module (EORTC QLQ-CX24).The scale ranges from 0 to 100, where higher scores represent better quality of life.

    Time frame: 2-years

07

Study locations

2 of 2 sites recruiting
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
    Recruiting
    • MAN NI HUANG, MD · Contacthuangmanni@csco.ac.cn · 8610-87788495
    • MAN NI HUANG, MD · Principal investigator
  • Lang Fang Campus of Cancer Hospital, Chinese Academy of Medical Sciences
    Langfang, Hebei 065001, China
    Recruiting
    • JU SHENG AN, MD · Contact0316-5918495
    • JU SHENG AN, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2030, 53 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 53 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684508
Lead sponsor
Manni Huang
Responsible party
Manni Huang (Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Sponsor-investigator
First posted
Jul 6, 2026
Start date
Jul 10, 2026
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Aug 5, 2026

Study contacts

MAN NI HUANG, MD
Contact
huangmanni@csco.ac.cn
8610-87788495
MAN NI HUANG, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion